Fuminori Taniguchi

Dr. Fuminori Taniguchi

Department of Obstetrics and Gynecology, Tottori University Faculty of Medicine, Yonago 683-8503, Japan
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2021 in Asian Journal of Endoscopic Surgery
Verified
Journal Article
Closed access
PDF file
HSHidefumi Shiroshita
Hidefumi Shiroshita
MIMasafumi Inomata
Masafumi Inomata
SAShigeo Akira
Shigeo Akira
HKHiroomi Kanayama
Hiroomi Kanayama
SYShigeki Yamaguchi
Shigeki Yamaguchi
YSYoshiharu Sakai
Yoshiharu Sakai

1 January 2011 in Frontiers in Bioscience-Elite
Verified
Journal Article
Closed access
Fuminori TaniguchiFuminori Taniguchi
Fuminori Taniguchi
AKApostolos Kaponis
Apostolos Kaponis
MIMasao Izawa
Masao Izawa
TKTomoiki Kiyama
Tomoiki Kiyama
IDImari Deura
Imari Deura
THTasuku Harada
Tasuku Harada
Apoptosis is a distinctive form of programmed cell death resulting in the efficient elimination of cells without eliciting an inflammatory response. Endometriosis is characterized by the presence of endometrial cells with capacity to avoid apoptosis outside the uterus. Apoptosis plays a fundamental role for the pathogenesis of endometriosis. Eutopic endometrium from women with endometriosis has increased expression of anti-apoptotic factor and decreased expression of pro-apoptotic factors compared with endometrium from healthy women. These differences could contribute to the survival of regurgitating endometrial cells into the peritoneal cavity and development of endometriosis. Increased apoptosis of Fas-bearing immune cells in the peritoneal cavity may leads to their decreased scavenger activity that eventually results in prolonged survival of ectopic endometrial cells in women with endometriosis. This study is a current review of the literatures focused on the physiological role of apoptosis in normal endometrium and alterations in regulation of apoptosis in eutopic and ectopic endometrium from women with endometriosis. The role of apoptosis in the treatment of endometriosis is also reviewed.

1 January 2010 in Women's Health
Verified
Journal Article
Open access
THTasuku Harada
Tasuku Harada
Fuminori TaniguchiFuminori Taniguchi
Fuminori Taniguchi
Dienogest (DNG), a progestin of 19-nortestosterone derivative, has good oral bioavailability and is highly selective for progesterone receptors. Owing to its antiovulatory, antiproliferative activities in endometrial cells, and its inhibitory effects on the secretion of cytokines, DNG is expected to be an effective treatment for endometriosis. Progesterone receptor-binding affinity is higher for DNG than for progesterone. Several pilot studies demonstrated that after 24 weeks of DNG treatment, there was a significant decrease in terms of dysmenorrhea, premenstrual pain, dyspareunia and diffuse pelvic pain. Most of the cases of genital bleeding occurring in the DNG treatment were spotting or breakthrough bleeding, which decreased with continued treatment and resolved either during treatment or after the end of treatment. The therapeutic effects of DNG 2 mg/day and norethisterone acetate 10 mg/day for endometriotic symptoms during a period of 24 weeks were almost similar. The only disadvantage of DNG seems to be the irregular bleeding. Good efficacy and tolerability of DNG in patients with endometriosis have been demonstrated in an open, randomized European clinical trial as compared with norethisterone acetate. In Japan, a Phase III, randomized, double-blind, multicenter, controlled trial was conducted to compare the efficacy and safety of DNG with intranasal buserelin acetate in patients with endometriosis. The study demonstrated that DNG is as effective as intranasal buserelin acetate in alleviating endometriosis symptoms, and causes less bone mineral density loss, resulting in the use on a commercial basis for endometriosis patients in Japan from 2008. This paper provides summarized data on this new promising drug for endometriosis.

31 January 2017 in American Journal of Reproductive Immunology
Verified
Journal Article
Closed access
PDF file
YAYukihiro Azuma
Yukihiro Azuma
Fuminori TaniguchiFuminori Taniguchi
Fuminori Taniguchi
KNKazuomi Nakamura
Kazuomi Nakamura
KNKei Nagira
Kei Nagira
YKYin Mon Khine
Yin Mon Khine
THTasuku Harada
Tasuku Harada

1 January 2023 in Reproductive Medicine and Biology
Verified
Journal Article
Open access
THTasuku Harada
Tasuku Harada
Fuminori TaniguchiFuminori Taniguchi
Fuminori Taniguchi
Sun-Wei GuoSun-Wei Guo
Sun-Wei Guo
YCYoung Min Choi
Young Min Choi
KBKutay Omer Biberoglu
Kutay Omer Biberoglu
YKYuval Kaufman
Yuval Kaufman
This is the first guidelines for adenomyosis from the Asian Society of Endometriosis and Adenomyosis.

3 September 2009 in Human Reproduction
Verified
Journal Article
Open access
PDF file
AWAyako Watanabe
Ayako Watanabe
Fuminori TaniguchiFuminori Taniguchi
Fuminori Taniguchi
MIMasao Izawa
Masao Izawa
KSKana Suou
Kana Suou
TUTakashi Uegaki
Takashi Uegaki
THTasuku Harada
Tasuku Harada
Decreased susceptibility of endometrial tissue to apoptosis may contribute to the pathogenesis of endometriosis. We investigate the role of survivin in the pathophysiology of endometriosis through the ability of ectopic and eutopic endometrial stromal cells (ESCs) to resist apoptosis. Ectopic ESCs were obtained from ovarian chocolate cysts in patients undergoing laparoscopic surgery (n = 22). Eutopic ESCs were isolated from endometrial tissue of cyclic premenopausal women undergoing hysterectomy for fibroids (n = 22). Purified stromal cells were studied in vitro. The number of surviving cells and activation of caspases were assessed by WST-8 assay and immunoblotting. Expression of inhibitor of apoptosis proteins (IAP) family members: cIAP1 (birc2), cIAP2 (birc3), XIAP (birc4), survivin (birc5) were examined using cDNA array and real-time RT–PCR. Effects of gene silencing by small inhibitor RNAs (siRNA) were examined by WST-8-assay, Annexin-V staining and immunoblotting. After staurosporine (SS) treatment, 55% of eutopic ESCs survived versus 70% of ectopic ESCs. Procaspase-3 or -7 was more intensely activated by SS treatment in eutopic than in ectopic ESCs (P < 0.01). mRNAs for IAP-family genes, such as cIAP-1, XIAP and survivin, were highly expressed in ectopic ESCs before SS treatment. The fold induction of survivin expression after SS treatment was higher in ectopic than eutopic ESCs (2.8 ± 0.27 versus 0.69 ± 0.07, respectively). Survivin gene silencing in SS-treated ectopic ESCs led to an increase of apoptotic cells (P < 0.05, versus control siRNA). We demonstrated that survivin plays a critical role in susceptibility of ESCs to apoptosis. Our results indicate that a survivin inhibitor may be effective as a novel treatment for endometriosis.